(Health-NewsWire.Net, July 26, 2017 ) Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention dizziness fatigue weakness irregular heart beat and congested lungs. Risk factors include high blood pressure diabetes sleep apnea alcoholism and coronary artery disease.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II and Phase I stages are 3 5 and 2 respectively.
Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular) . - The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular)
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Left Ventricular Dysfunction (Cardiovascular) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Left Ventricular Dysfunction (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles Acorda Therapeutics Inc Amgen Inc Bayer AG F. Hoffmann-La Roche Ltd Innopharmax Inc Les Laboratoires Servier SAS Quantum Genomics SA RedHill Biopharma Ltd TiGenix NV
List of Tables Number of Products under Development for Left Ventricular Dysfunction H2 2017 Number of Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 Number of Products by Stage and Target H2 2017 Number of Products by Stage and Mechanism of Action H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Left Ventricular Dysfunction-Pipeline by Acorda Therapeutics Inc H2 2017 Left Ventricular Dysfunction-Pipeline by Amgen Inc H2 2017 Left Ventricular Dysfunction-Pipeline by Bayer AG H2 2017 Left Ventricular Dysfunction-Pipeline by F. Hoffmann-La Roche Ltd H2 2017 Left Ventricular Dysfunction-Pipeline by Innopharmax Inc H2 2017 Left Ventricular Dysfunction-Pipeline by Les Laboratoires Servier SAS H2 2017 Left Ventricular Dysfunction-Pipeline by Quantum Genomics SA H2 2017 Left Ventricular Dysfunction-Pipeline by RedHill Biopharma Ltd H2 2017 Left Ventricular Dysfunction-Pipeline by TiGenix NV H2 2017 Left Ventricular Dysfunction-Dormant Projects H2 2017 Left Ventricular Dysfunction-Discontinued Products H2 2017